A process for preparing a phytosomal nanocomplex
Patent Information
- Application Number
- IN202521118924
- Authority / Receiving Office
- IN · IN
- Patent Type
- Patents
- Current Assignee / Owner
- Filing Date
- 2025-11-28
- Publication Date
- 2026-07-10
- Estimated Expiration
- 2045-11-28
AI Technical Summary
Existing herbal bioactive compounds, such as those from Centella asiatica and Bauhinia variegata, face challenges with poor solubility, instability, and limited bioavailability, particularly in traversing the blood-brain barrier, due to conventional drug delivery techniques that often result in chemical degradation and uneven particle dispersion.
A phytosomal formulation using a 1:1 weight ratio of soy lecithin with a solvent mixture of 1:2 ethanol to tetrahydrofuran (THF) is developed through rotary evaporation, followed by hydration, sonication, and freeze-drying to create stable nanoscale phytosomes for enhanced solubility and BBB permeability.
The process results in uniform, nanoscale phytosomes with improved encapsulation efficiency and stability, facilitating effective brain-targeted delivery and increased bioavailability of herbal extracts.
Abstract
Description
FIELD OF THE INVENTIONThe present invention relates to the field of pharmaceutical and nutraceutical formulation technology.More particularly, the present invention relates to a process for preparing a phytosomal nanocomplex toenhance the bioavailability and therapeutic efficacy of plant-derived extracts.BACKGROUND OF THE INVENTIONHerbal medicines have attracted a lot of scientific and therapeutic interest because of their variedpharmacological activities and minimal side effects. However, one of the major challenges associatedwith herbal bioactives is their poor solubility, instability, and limited bioavailability, which restricts theirclinical efficacy. Plant-derived compounds such as triterpenoids, flavonoids, saponins, and phenolic acidsare commonly present in extracts of Centella asiatica and Bauhinia variegate exhibit strong antioxidant,anti-inflammatory, and neuroprotective activities. Despite their strong therapeutic potential, their limitedpermeability in aqueous conditions and incapacity to effectively traverse biological barriers like theblood-brain barrier (BBB) limit their pharmacological efficacy.Several conventional drug delivery techniques, such as liposomes, nanoemulsions, solid lipidnanoparticles, and polymeric micelles, have been investigated to address these issues. These systemsoften have disadvantages such limited encapsulation efficiency, phytoconstituent chemical degradation,and costly manufacturing, even if they have shown gains in solubility and stability. Many of theseformulations fail to maintain the structural integrity of the active phytochemicals, which leads todecreased pharmacodynamic efficacy.The introduction of phytosomal technology marked an important advancement in improving thebioavailability of plant-based therapeutics. Phytosomes are complexes formed between standardized plantextracts and phospholipids, typically phosphatidylcholine, which enhance the lipophilicity and membranepermeability of the bioactive compounds. Existing methods of phytosome preparation commonly utilizeorganic solvents such as dichloromethane, chloroform, or acetone; however, these solvents may leavetoxic residues, present safety concerns, and sometimes fail to produce uniform nanoscale particles.Phytosomal preparations of Centella asiatica extract utilizing ethanol and phosphatidylcholine have beenreported in earlier studies, showing increased skin penetration and antioxidant activity. Additionally,extracts from Bauhinia variegata have been encapsulated in lipid-based nanocarriers to boostbioavailability. However, these outdated methods often result in poor formulation stability, unevenparticle dispersion, and agglomeration during storage. Furthermore, the potential use of tetrahydrofuran(THF) as a co-solvent with ethanol in phytosomal formulations remains little unexplored. THF has greatersolvation capacities and contributes to better miscibility between hydrophilic and lipophilic components,leading to uniform nanoscale complexation.Therefore, to overcome the limitations of existing systems, there is a need to develop an efficientphytosomal formulation technique that not only enhances solubility and stability but also improves thepermeability of the bioactive compounds across the blood-brain barrier. The present invention addressesthese shortcomings by introducing a tetrahydrofuran-assisted soy lecithin-based phytosomal for Centellaasiatica and Bauhinia variegata extracts. This approach offers enhanced nanoscale uniformity, betterencapsulation efficiency, improved dispersion in aqueous media, and superior potential for brain-targeteddelivery compared to existing herbal delivery systems.SUMMARY OF THE INVENTIONThe present invention discloses a process for developing two distinct phytosomal formulations i.e. aphytosome derived from an extract of Centella asiatica and a phytosome derived from an extract ofBauhinia variegate. The formulation employs a 1:1 weight-to-weight ratio of soy lecithin, combined witha solvent solution consisting of a 1:2 ratio of ethanol to tetrahydrofuran (THF). The development of theseformulations utilizes the technique of rotary evaporation, resulting in stable nanoscale phytosomes thatexhibit enhanced solubility and demonstrate potential for administration to the brain.In an embodiment, a phytosomal nanocomplex composition is disclosed. The composition comprising 50-0 wt. % of ethanolic herbal extracts of Bauhinia variegata and Centella asiatica; and 50-100 wt. % of aphytosomal mixture containing: 100 mg of soy lecithin; 10 mL of ethanol; and 20 mL of tetrahydrofuran(THF).In another embodiment, a process for preparing a phytosomal nanocomplex is disclosed. The processincludes preparing ethanolic herbal extracts of Bauhinia variegata and Centella asiatica.The process further includes preparing 50-100 wt. % of phytosomal mixture upon treating 50-0 wt. % ofethanolic herbal extracts of Bauhinia variegata and Centella asiatica with 100 mg of soy lecithin, 10 mLof ethanol, and 20 mL of tetrahydrofuran (THF).The process further includes subjecting the mixture to rotary evaporation at 40-45°C under reducedpressure to obtain a thin lipid-herbal film.The process further includes hydrating the thin film with distilled water and gently swirling for 30minutes at room temperature to promote vesicle formation.The process further involves washing the hydrated dispersion with n-hexane to remove non-encapsulatedherbal constituents and unbound phospholipids.The process further includes sonicating the dispersion using a probe sonicator to reduce vesicle size andobtain nanoscale phytosomal vesicles.The process further includes freeze-drying the dispersion at -20°C for a period exceeding 24 hours toobtain a stable, dried phytosomal nanocomplex.An object of the present invention is to develop phytosome formulations utilizing extracts from Centellaasiatica and Bauhinia variegata,Another object of the present invention is to enhance the stability, bioavailability, and therapeuticpotential of the extracts through methodical formulation and characterization approaches,Yet, another object of the present invention is to characterize the formulated phytosomes using particlesize and polydispersity index analysis, UV-Visible spectroscopy, X-ray diffraction, differential scanningcalorimetry, Fourier transform infrared spectroscopy, high-performance thin-layer chromatography, andtransmission electron microscopy, andYet, another object of the present invention is to provide a phospholipid-based nanocarrier system capableof facilitating the crossing of the blood-brain barrier (BBB), thus extending the potential of Centellaasiatica and Bauhinia variegata extracts for neurological and cognitive treatments.To further clarify advantages and features of the present disclosure, a more particular description of theinvention will be rendered by reference to specific embodiments thereof, which is illustrated in theappended drawings. It is appreciated that these drawings depict only typical embodiments of the inventionand are therefore not to be considered limiting of its scope. The invention will be described and explainedwith additional specificity and detail with the accompanying drawings.BRIEF DESCRIPTION OF FIGURESThese and other features, aspects, and advantages of the present disclosure will become better understoodwhen the following detailed description is read with reference to the accompanying drawings in whichlike characters represent like parts throughout the drawings, wherein:Figure 1 illustrates a flow diagram of a process for preparing a phytosomal nanocomplex in accordancewith an embodiment of the present disclosure;Figure 2 illustrates UV-Visible Spectral Analysis of CAE and CAP in accordance with an embodimentof the present disclosure;Figure 3 illustrates particle size analysis of CAP in accordance with an embodiment of the presentdisclosure;Figure 4 illustrates fourier transform infrared spectroscopy (FTIR) analysis in accordance with anembodiment of the present disclosure;Figure 5 illustrates table 1 depicts FTIR spectral data displaying the peak positions (cm⁻¹), associatedvibrational modes, and identified functional groups for the analyzed sample in accordance with anembodiment of the present disclosure;Figure 6 illustrates differential scanning calorimetry (DSC) analysis of CAP in accordance with anembodiment of the present disclosure;Figure 7 illustrates XRD analysis of CAP in accordance with an embodiment of the present disclosure;Figure 8 illustrates Transmission Electron Microscopy (TEM) analysis of CAP in accordance with anembodiment of the present disclosure;Figure 9 illustrates High Performance Thin- Layer Chromatography (HPTLC) analysis of CAE and CAPformulation in accordance with an embodiment of the present disclosure;Figure 10 illustrates Table 2 depicts the HPTLC profile of CAE in accordance with an embodiment ofthe present disclosure;Figure 11 illustrates Table 3 depicts the HPTLC profile of the Phytosome in accordance with anembodiment of the present disclosure;Figure 12 illustrates Characterization of Bauhinia variegata Phytosome (BVP) in accordance with anembodiment of the present disclosure;Figure 13 illustrates Fourier Transform Infrared Spectroscopy (FTIR) Analysis of BVE and BVP inaccordance with an embodiment of the present disclosure;Figure 14 illustrates Differential Scanning Calorimetry (DSC) analysis of BVP in accordance with anembodiment of the present disclosure;Figure 15 illustrates X-Ray Diffraction Analysis of BVP in accordance with an embodiment of thepresent disclosure;Figure 16 illustrates TEM analysis of BVP in accordance with an embodiment of the present disclosure;andFigure 17 illustrates HPTLC analysis of BVE and BVP in accordance with an embodiment of the presentdisclosure.Further, skilled artisans will appreciate that elements in the drawings are illustrated for simplicity andmay not have been necessarily been drawn to scale. For example, the flow charts illustrate the method interms of the most prominent steps involved to help to improve understanding of aspects of the presentdisclosure. Furthermore, in terms of the construction of the device, one or more components of the devicemay have been represented in the drawings by conventional symbols, and the drawings may show onlythose specific details that are pertinent to understanding the embodiments of the present disclosure so asnot to obscure the drawings with details that will be readily apparent to those of ordinary skill in the arthaving benefit of the description herein.DETAILED DESCRIPTION:For the purpose of promoting an understanding of the principles of the invention, reference will now bemade to the embodiment illustrated in the drawings and specific language will be used to describe thesame. It will nevertheless be understood that no limitation of the scope of the invention is therebyintended, such alterations and further modifications in the illustrated system, and such further applicationsof the principles of the invention as illustrated therein being contemplated as would normally occur to oneskilled in the art to which the invention relates.It will be understood by those skilled in the art that the foregoing general description and the followingdetailed description are exemplary and explanatory of the invention and are not intended to be restrictivethereof.Reference throughout this specification to "an aspect", "another aspect" or similar language means that aparticular feature, structure, or characteristic described in connection with the embodiment is included inat least one embodiment of the present disclosure. Thus, appearances of the phrase "in an embodiment","in another embodiment" and similar language throughout this specification may, but do not necessarily,all refer to the same embodiment.The terms "comprises", "comprising", or any other variations thereof, are intended to cover a nonexclusive inclusion, such that a process or method that comprises a list of steps does not include onlythose steps but may include other steps not expressly listed or inherent to such process or method.Similarly, one or more devices or sub-systems or elements or structures or components proceeded by"comprises..." does not, without more constraints, preclude the existence of other devices or other subsystems or other elements or other structures or other components or additional devices or additional subsystems or additional elements or additional structures or additional components.Unless otherwise defined, all technical and scientific terms used herein have the same meaning ascommonly understood by one of ordinary skill in the art to which this invention belongs. The system,methods, and examples provided herein are illustrative only and not intended to be limiting.Embodiments of the present disclosure will be described below in detail with reference to theaccompanying drawings.In an embodiment, a phytosomal nanocomplex composition is disclosed. The composition comprising:50-0 wt. % of ethanolic herbal extracts of Bauhinia variegata and Centella asiatica; and 50-100 wt. % of aphytosomal mixture containing: 100 mg of soy lecithin; 10 mL of ethanol; and 20 mL of tetrahydrofuran(THF).Referring to Figure 1, a flow chart of a process for preparing a phytosomal nanocomplex is illustrated inaccordance with an embodiment of the present disclosure. At step (102), process (100) includes preparingethanolic herbal extracts of Bauhinia variegata and Centella asiatica.At step (104), process (100) includes preparing 50-100 wt. % of phytosomal mixture upon treating 50-0wt. % of ethanolic herbal extracts of Bauhinia variegata and Centella asiatica with 100 mg of soy lecithin,10 mL of ethanol, and 20 mL of tetrahydrofuran (THF).At step (106), process (100) includes subjecting the mixture to rotary evaporation at 40-45°C underreduced pressure to obtain a thin lipid-herbal film.At step (108), process (100) includes hydrating the thin film with distilled water and gently swirling for30 minutes at room temperature to promote vesicle formation.At step (110), process (100) includes washing the hydrated dispersion with n-hexane to remove nonencapsulated herbal constituents and unbound phospholipids.At step (112), process (100) includes sonicating the dispersion using a probe sonicator to reduce vesiclesize and obtain nanoscale phytosomal vesicles.At step (114), process (100) includes freeze-drying the dispersion at -20°C for a period exceeding 24hours to obtain a stable, dried phytosomal nanocomplex.In a further embodiment, the ethanolic herbal extract preparation comprising: drying and pulverizing plantmaterials of Bauhinia variegata and Centella asiatica separately to obtain a coarse powder; subjectingeach powdered material to a Soxhlet extraction using ethanol as a solvent, wherein the extraction iscarried out at a temperature ranging from 50°C to 60°C for a period of 6-8 hours to ensure efficientextraction of phytoconstituents; filtering the obtained ethanolic extract through a Whatman filter paper toremove residual plant debris and impurities; and concentrating the filtrate using a rotary evaporator underreduced pressure at a temperature between 40°C and 50°C to remove ethanol and obtain a thick, semisolid herbal extract; wherein the obtained extract is collected and stored separately in sterile beakers forsubsequent phytosomal formulation.In some embodiments, the plant powder-to-solvent ratio is maintained between 1:5 and 1:10 (w / v) tooptimize extraction yield and efficiency.In one embodiment, the phytosomal mixture preparation comprising: introducing 100 mg of ethanolicherbal extracts of Bauhinia variegata and Centella asiatica into a sterilized round-bottom flask; adding100-200 mg of soy lecithin to the flask in a weight-to-weight ratio ranging from 1:1 to 1:2 with respect tothe herbal extract; preparing a solvent mixture comprising 10 mL of ethanol and 20 mL of tetrahydrofuran(THF) and adding to the flask containing the extract and lecithin; and subjecting the resultant mixture to amagnetic stirring at room temperature for 30 to 45 minutes to achieve complete dissolution and uniformmixing, thereby forming a homogeneous phytosomal mixture suitable for subsequent thin film formation.In one embodiment, the temperature during mixing is maintained between 25°C and 30°C to preserve thethermolabile phytoconstituents of the herbal extract.In one embodiment, the thin phytosomal film is obtained by: subjecting the phytosomal mixture to arotary evaporation; maintaining the rotary evaporation under a controlled temperature range of 40°C to45°C and under reduced pressure conditions; rotating the round-bottom flask to ensure uniform solventremoval and even film deposition; and evaporating the solvent mixture until a thin, dry phytosomal film isformed on the inner wall of the flask, wherein the obtained thin film serves as a precursor for hydrationand nanoscale vesicle formation.In another embodiment, the rotary evaporation is carried out at a vacuum pressure ranging from 200 to300 mbar to prevent thermal degradation of phytoconstituents during solvent removal, wherein theevaporation continues for a duration between 30 and 60 minutes until complete dryness of the solventmixture is achieved.In another embodiment, hydration is carried out using distilled or deionized water at a temperaturebetween 25°C and 35°C to ensure optimal swelling and vesicle formation, wherein probe sonication isperformed at an amplitude of 40%-60% for a duration of 5-10 minutes to achieve a vesicle size below250 nanometers.In another embodiment, the lyophilization is performed at a condenser temperature ranging from -45°Cto -55°C and a chamber pressure between 0.01 and 0.05 mbar to promote sublimation of ice withoutstructural collapse of phytosomal vesicles, wherein the frozen dispersion is pre-frozen using a controlledrate freezer to minimize ice crystal formation and preserve vesicle integrity, wherein a cryoprotectantselected from mannitol, trehalose, or sucrose is optionally added to the dispersion prior to freezing in anamount ranging from 1% to 5% w / v to prevent aggregation during freeze-drying.The present invention relates to the development of a process for preparing phytosomal nanocomplexformulation by utilizing the herbal extracts of Bauhinia variegata and Centella asiatica, to enhancebioavailability and therapeutic efficacy. The formulation employs tetrahydrofuran (THF) and ethanol assolvents in a ratio of 20 mL THF to 10 mL ethanol, with soy lecithin serving as the carrier. In theformulation process, the selected herbal extract is combined with the soy lecithin in a weight ratio of 1:1or 1:2 (extract to lecithin). The solvent of THF and ethanol is used to dissolve the componentsthoroughly. A thin lipid film is produced by rotary evaporation at 40°C, after which the resulting driedfilm is hydrated with hexane to facilitate the development of phytosomes.Further, the prepared phytosomal formulations are characterized through particle size and polydispersityindex (PDI) analysis, UV-Visible spectroscopy, X-ray diffraction (XRD), differential scanningcalorimetry (DSC), Fourier-transform infrared spectroscopy (FTIR), high-performance thin-layerchromatography (HPTLC), and transmission electron microscopy (TEM). These analyses confirm thesuccessful formation, stability, and uniformity of the phytosomal complexes. The phospholipid-basedcarrier promotes effective crossing of the blood-brain barrier (BBB), while the nanoscale particle sizeenhances absorption and bioavailability. Additionally, the formulation exhibits improved dispersion andsolubility in aqueous environments, along with enhanced physicochemical stability and bio-efficacy.The present invention provides a systematic and reproducible process for the formulation of phytosomalnanocomplexes incorporating herbal extracts of Bauhinia variegata or Centella asiatica to enhancebioavailability and therapeutic potential. The process begins with the preparation of ethanolic extracts ofthe plant materials using the Soxhlet extraction. The extracts are subsequently filtered and concentratedusing a rotary evaporator, and the concentrated extracts are collected separately in clean beakers forfurther processing. In the next step, the phytosomal mixture is prepared by introducing 100 mg of theherbal extract into a sterilized round-bottom flask, followed by the addition of soy lecithin in a 1:1 or 1:2weight-to-weight ratio. A solvent comprising 10 mL of ethanol and 20 mL of tetrahydrofuran (THF) isadded to dissolve the components completely, and the mixture is stirred magnetically for 30 to 45 minutesat room temperature to achieve homogeneity.The homogeneous solution then undergoes rotary evaporation under reduced pressure at a controlledtemperature of 40-45°C, enabling solvent removal and the formation of a thin lipid film on the innersurface of the flask. This thin film is subsequently hydrated with distilled water and gently swirled for 30minutes to facilitate the uniform formation of vesicles. To remove unbound or non-encapsulatedmaterials, the mixture is washed with n-hexane. The hydrated dispersion is then subjected to probesonication to reduce vesicle size and achieve a more uniform nanoscale distribution. Followingsonication, the resulting dispersion is frozen overnight at -20°C to ensure structural stability. Finally,lyophilization is performed for over 24 hours using a freeze dryer to obtain a dry, stable phytosomalnanocomplex powder for enhanced solubility, bioavailability, and therapeutic efficacy of the herbalextracts.Figure 2 illustrates UV-Visible Spectral Analysis of CAE and CAP in accordance with an embodimentof the present disclosure. The characterization of Centella asiatica phytosome (CAP) is carried out usingUV-Visible spectral analysis to determine the optical properties, compound stability, and possibleinteractions between the bioactive constituents and the phospholipid matrix. Further, to identify thecharacteristic absorbance peaks (λmax) and the presence of phytochemical groups, the UV-Visibleprofile of the CAE and the CAP sample are analyzed and compared. The UV-Visible spectra of theextract reveal a strong absorbance peak at 406 nm, which corresponds to terpenoid, phenolic, andflavonoid compounds key bioactive constituents naturally present in Centella asiatica. Additionalabsorbance peaks are observed at 536 nm, indicating minor chromophoric groups or conjugated pigments,and at 670 nm, with a relatively lower absorbance value of 0.1862, suggesting a reduced concentration ofcertain compounds or limited absorption efficiency at this wavelength.The CAP sample shows a noticeable change in spectral behavior upon phytosome formation, especiallythe appearance of an absorbance peak at 669 nm, which is linked to the creation of a drug-lipid complex.This shift represents a change in the molecules electronic environment due to complexation between thebioactive chemicals and soy lecithin, which results in the development of chromophoric features in thevisible spectrum. The effective encapsulation of phytoconstituents within the phospholipid matrix isconfirmed by comparing the spectra of the crude extract and CAP. The retention of the 406 nm peak inthe extract spectrum validates the presence of triterpenoids, flavonoids, and phenolic compounds, whilethe new spectral pattern in the CAP indicates chemical interaction and enhanced structural organization.Overall, the UV-Visible analysis demonstrates effective phytosome formation, confirming that bioactivecomponents from Centella asiatica are successfully complexed within the phospholipid network,resulting in altered optical properties and improved formulation stability.Figure 3 illustrates particle size analysis of CAP in accordance with an embodiment of the presentdisclosure. The particle size analysis of the Centella asiatica phytosome (CAP) reveals the formation of auniform nanometric dispersion, confirming the successful development of a stable phytosomal. The CAPformulation's average particle diameter is found to be 312 nm, suggesting that the vesicles are in thenanoscale range that is ideal for effective absorption and cellular uptake. The phytosomal formulationshows good homogeneity, which is necessary to maintain consistency in drug delivery performance, asseen by the limited size distribution. The formulation's monodisperse character is further supported by thepolydispersity index (PDI) of 0.141, which denotes exceptional colloidal stability and a uniform particlesize distribution. Further, the structural integrity of the vesicular system is confirmed by a low PDI score,which indicates the lack of aggregation or size variability. Overall, the results demonstrate that the CAPformulation has a high degree of homogeneity and an ideal particle size qualities that are essential forenhanced bioavailability, stability, and efficient transport of the bioactive chemicals obtained fromCentella asiatica.Figure 4 illustrates Fourier transform infrared spectroscopy (FTIR) analysis in accordance with anembodiment of the present disclosure. The FTIR spectra of CAE and CAP revealed significant spectraldifferences, indicating the successful formation of phytosomes. In the CAP spectrum, a distinct new peakis identified at 1740 cm⁻¹, which corresponds to the ester carbonyl (C=O) stretch of phospholipids and isabsent in the CAE spectrum. This observation, as represented in Figure 5 (table 1), confirms the effectiveincorporation of phospholipids into the formulation. Additionally, enhanced peaks at 1033 cm⁻¹ and 1164cm⁻¹ are detected, associated with C-O-C stretching vibrations. This suggests robust interactions betweenthe extract and the phospholipid molecules. New peaks in the fingerprint region (400-600 cm⁻¹) furthersupport the presence of characteristic phospholipid structures. Furthermore, shifts in the O-H and C-Hstretching regions point to the formation of hydrogen bonds and possible complexation between thehydroxyl groups of the extract and the polar head groups of the phospholipid. Collectively, these spectralmodifications confirm that a stable phytosomal complex has been successfully formed in the CAPformulation.Figure 6 illustrates differential scanning calorimetry (DSC) analysis in accordance with an embodimentof the present disclosure. The DSC analysis of the Centella asiatica phytosome (CAP) provides crucialevidence of successful encapsulation and structural transformation of the bioactive compounds within thephospholipid matrix. In the DSC thermogram of the Centella asiatica extract (CAE), a distinctendothermic melting peak appears in the range of 135-145 °C, which is characteristic of asiaticoside in itscrystalline form. In contrast, this sharp melting peak disappears completely in the CAP thermogram,indicating that the asiaticoside has transitioned from a crystalline to an amorphous state as a result ofencapsulation within the phospholipid framework. Additionally, the CAP thermogram exhibits a newexothermic peak at approximately 342.48 °C, corresponding to the thermal degradation of the newlyformed drug-lipid complex. This shift further confirms the establishment of strong molecular interactionsbetween the phytoconstituents and the phospholipid components. The overall DSC profile demonstratesthat the CAP formulation possesses enhanced thermal stability, an amorphous structural nature, and awell-integrated complexation of bioactive compounds within the lipid matrix, validating the successfulformation of a stable phytosomal nanocomplex.Figure 7 illustrates XRD analysis of CAP in accordance with an embodiment of the present disclosure.The X-ray diffraction (XRD) pattern of the CAP sample reveals a broad peak centered around 2θ ≈ 20°,suggesting that the material exhibits an amorphous or poorly crystalline structure. The lack of sharp anddistinct diffraction peaks indicates the absence of long-range atomic order; a characteristic typicallyassociated with crystalline materials. Instead, the broad halo implies that the material is predominantlyamorphous, likely due to molecular dispersion or structural disorder. This phenomenon is commonlyobserved in formulations based on natural products, such as phytoconstituent-loaded carriers or polymericsystems, where the active compound is integrated within a matrix that suppresses crystallinity.Consequently, the XRD results affirm that the CAP sample has an amorphous nature, which may enhanceits solubility and bioavailability in pharmaceutical or nutraceutical applications.Figure 8 illustrates Transmission Electron Microscopy (TEM) analysis of CAP in accordance with anembodiment of the present disclosure. The TEM image reveals a well-defined spherical vesicle,representative of a phytosomal or liposomal system. This vesicle features a distinct core-shell structure,with a dense inner region enveloped by a lighter outer layer, indicating the presence of a lipid bilayer.Although the characteristic bilayer appearance-comprised of two parallel electron-dense lines-is notdistinctly visible, the variations in peripheral contrast suggest a bilayer arrangement. Such differences invisualization are frequently attributed to the staining techniques employed and the resolution of theimaging instrument. The estimated size of the vesicle, based on the 500 nm scale bar, is consistent withthe nanometric range typical of phytosomal formulations. This structural observation is in accordancewith previous TEM studies of lipid-based carriers containing phospholipids and natural compounds,which have reported similar morphologies.Figure 9 illustrates High Performance Thin- Layer Chromatography (HPTLC) analysis of CAE and CAPformulation in accordance with an embodiment of the present disclosure. The HPTLC chromatogram ofCAE and CAP formulations distinctly demonstrates triterpenoid separation, showing well-defined peaksat specific Rf values and AUC. This clearly indicates the relative abundance of the phytoconstituentspresent.Figure 10 illustrates Table 2 depicts the HPTLC profile of CAE, which effectively illustrates keyparameters, including the retention factor (Rf), compound identification, peak height, area under the curve(AUC), and the percentage area contribution of each component. This comprehensive analysis enhancesour understanding of the profile's characteristics and facilitates further research and application.Figure 11 illustrates Table 3 depicts the HPTLC profile of the Phytosome, thoughtfully presents theretention factor (Rf), compound identification, peak height, area under the curve (AUC), and thepercentage contribution of each component. This detailed analysis aims to provide you with a clearunderstanding of the essential characteristics of the Phytosome and its components.There are significant variations in peak number, Rf values, and phytoconstituent distribution between theethanolic CAE and CAP formulations when compared using HPTLC. Asiatic acid (Rf 0.58), asiaticoside(Rf 0.44), and madecassoside (Rf 0.70) accounted for 46.57%, 29.32%, and 13.15% of the total area,respectively, of the extract's six peaks, which collectively represented for 89% of the composition. On theother hand, complexation effects are noticeable in the phytosomal formulation, which showed five peakswith reduced intensity and changed Rf values (Asiatic acid 0.55, asiaticoside 0.41, and madecassoside0.67). Significant contributions are made by two unidentified peaks at Rf 0.05 and 0.21 (37.35% and10.31%), which may indicate excipient interactions or recently formed complexes. The presence ofsignificant triterpenoids supports the phytosome's promise for increased stability and bioavailability byconfirming effective encapsulation and phytochemical retention in even with all of these modifications.Figure 12 illustrates Characterization of Bauhinia variegata Phytosome (BVP) in accordance with anembodiment of the present disclosure. A stable, uniform and monodisperse nano vesicular system isindicated by the BVP formulation's low PDI of 0.164 and mean particle diameter of approximately 309.6nm. These factors promote the successful formulation and possible efficacy of the BVP, which ispredicted to have increased bioavailability, higher entrapment efficiency, and improved therapeuticperformance. They are also favourable for nanocarrier-based drug delivery.Figure 13 illustrates Fourier Transform Infrared Spectroscopy (FTIR) Analysis of BVE and BVP inaccordance with an embodiment of the present disclosure. Successful phytosome production is indicatedby specific spectrum shifts found in the BVP formulation's FTIR analysis. One important finding is thatthe large O-H stretching signal at 3319 cm⁻¹ disappeared indicating hydrogen bonding between thephospholipid molecules and the phytoconstituents' hydroxyl groups. Furthermore, the presence or shift ofan ester carbonyl (C=O) stretching band at around 1740 cm⁻¹ indicates that phospholipids have beenincorporated into the complex. In the 1056-1088 cm⁻¹ range, enhanced and shifted C-O-C ether bandsfurther show that the extract contents and the phospholipid structure have significant interactions. Thedevelopment of a stable phytosomal system is confirmed by minor changes seen in CH₂ and other C-Ostretching regions which suggest the presence of molecular interactions rather than just physical mixing.Figure 14 illustrates Differential Scanning Calorimetry (DSC) analysis of Bauhinia variegata Phytosome(BVP) in accordance with an embodiment of the present disclosure. The BVP formulation indicates thatcomplex formation based on thermal properties is successful. The existence of a large exothermic peak at346.91°C suggests that the structure is amorphous and stable. Furthermore, the lack of melting peaksspecific to the extract (~100-150 °C) further confirms that flavonoids are well encapsulated inside thephospholipid matrix. The phospholipid bilayer synthesis is supported by the phase change at about69.37°C, confirming the properties of phytosomes.Figure 15 illustrates X-Ray Diffraction Analysis of BVP in accordance with an embodiment of thepresent disclosure. The XRD pattern of the sample designated as BVP is analyzed to ascertain its physicalstate. The diffractogram reveals a broad peak centered at 2θ = 20°, with no evidence of sharp or distinctdiffraction peaks. This broad halo is characteristic of amorphous materials, indicating the absence ofcrystallinity within the sample. The observed lack of sharp peaks further confirms that thephytoconstituents are molecularly dispersed within the phospholipid matrix, signifying that no crystallinedrug or component exists in the formulation. These findings suggest the successful formation of anamorphous phytosome complex, which may enhance solubility and bioavailability in comparison to thecrystalline form.Figure 16 illustrates TEM analysis of BVP in accordance with an embodiment of the present disclosure.The TEM image displays a cluster of nanosized vesicular structures, which are indicative of themorphology typically associated with phytosomes. These vesicles demonstrate a relatively uniformspherical to slightly irregular shape, characterized by a lighter core encased in a denser outer region,suggesting a lipid-based architecture. Although the classical bilayer structure, denoted by two distinctparallel electron-dense lines, is not distinctly resolved in this image, the observed peripheral contrastimplies the potential presence of a bilayer membrane. The image supports the existence of lipid vesicles;however, while the morphological features strongly indicate bilayer-enclosed vesicles, definitiveidentification of the bilayer structure remains to be fully established.Figure 17 illustrates HPTLC analysis of BVE and BVP in accordance with an embodiment of the presentdisclosure. The comparative analysis utilizing HPTLC between the BVE and the BVP revealed significantdistinctions in their flavonoid profiles, thereby highlighting the effect of phytosome encapsulation on thedistribution and availability of these compounds. Key flavonoids, including kaempferol, quercetin,luteolin, rutin, and apigenin, are identified, each exhibiting distinct retention factor (Rf) values. Theextract demonstrated the presence of 10 peaks, indicating a variety of phytoconstituents, whereas thephytosome exhibited 9 peaks with reduced intensities. A notable decrease in the area under the curve(AUC) is observed for kaempferol (decreasing from 19702.7 to 1116.1), rutin (from 21225.0 to 1968.2),and apigenin (from 6982.0 to 889.8), suggesting potential entrapment or diminished surface availabilitywithin the phytosomal matrix. Conversely, flavonoids such as myricetin exhibited an increase in AUC(from 319.0 to 1091.5), along with a flavone derivative, which rose from 292.5 to 1735.5. Thisenhancement may be attributed to improved solubility or stability within the formulation. Additionally,alterations in Rf values are noted, implying potential changes in compound polarity as a result ofencapsulation. Notably, a luteolin derivative (Rf 0.95) detected in the extract is absent in the phytosomalformulation, suggesting possible degradation or non-incorporation. Collectively, these observationsunderscore the restructuring of the flavonoid profile within the phytosomal system, which maysignificantly impact the formulation's pharmacological efficacy and bioavailability.The current study successfully formulated and characterized extracts from Centella asiatica and Bauhiniavariegata to develop a phytosomal formulation intended to enhance solubility, stability, bioavailabilityacross the blood-brain barrier (BBB), and therapeutic efficacy of their bioactive constituents. Thephytosomal formulation exhibited nano-sized vesicles with commendable stability and an amorphousnature, as demonstrated through various analytical methods, including particle size analysis, UVspectroscopy, differential scanning calorimetry (DSC), X-ray diffraction (XRD), Fourier-transforminfrared spectroscopy (FTIR), high-performance thin-layer chromatography (HPTLC), and transmissionelectron microscopy (TEM).The drawings and the forgoing description give examples of embodiments. Those skilled in the art willappreciate that one or more of the described elements may well be combined into a single functionalelement. Alternatively, certain elements may be split into multiple functional elements. Elements fromone embodiment may be added to another embodiment. For example, orders of processes described hereinmay be changed and are not limited to the manner described herein. Moreover, the actions of any flowdiagram need not be implemented in the order shown; nor do all of the acts necessarily need to beperformed. Also, those acts that are not dependent on other acts may be performed in parallel with theother acts. The scope of embodiments is by no means limited by these specific examples. Numerousvariations, whether explicitly given in the specification or not, such as differences in structure, dimension,and use of material, are possible. The scope of embodiments is at least as broad as given by the followingclaims.Benefits, other advantages, and solutions to problems have been described above with regard to specificembodiments. However, the benefits, advantages, solutions to problems, and any component(s) that maycause any benefit, advantage, or solution to occur or become more pronounced are not to be construed asa critical, required, or essential feature or component of any or all the claims.
Claims
1. A phytosomal nanocomplex composition comprising: 50-0 wt. % of ethanolic herbal extracts of Bauhinia variegata and Centella asiatica; and 50-100 wt. % of a phytosomal mixture containing: 100 mg of soy lecithin; 10 mL of ethanol; and 20 mL of tetrahydrofuran (THF).
2. A process for preparing a phytosomal nanocomplex, comprising: preparing ethanolic herbal extracts of Bauhinia variegata and Centella asiatica; preparing 50-100 wt. % of phytosomal mixture upon treating 50-0 wt. % of ethanolic herbal extracts of Bauhinia variegata and Centella asiatica with 100 mg of soy lecithin, 10 mL of ethanol, and 20 mL of tetrahydrofuran (THF); subjecting the mixture to rotary evaporation at 40-45°C under reduced pressure to obtain a thin lipid- herbal film; hydrating the thin film with distilled water and gently swirling for 30 minutes at room temperature to promote vesicle formation; washing the hydrated dispersion with n-hexane to remove non-encapsulated herbal constituents and unbound phospholipids; sonicating the dispersion using a probe sonicator to reduce vesicle size and obtain nanoscale phytosomal vesicles; and freeze-drying the dispersion at -20°C for a period exceeding 24 hours to obtain a stable, dried phytosomal nanocomplex.
3. The process as claimed in claim 2, wherein the ethanolic herbal extract preparation comprising: drying and pulverizing plant materials of Bauhinia variegata and Centella asiatica separately to obtain a coarse powder; subjecting each powdered material to a Soxhlet extraction using ethanol as a solvent, wherein the extraction is carried out at a temperature ranging from 50°C to 60°C for a period of 6-8 hours to ensure efficient extraction of phytoconstituents; filtering the obtained ethanolic extract through a Whatman filter paper to remove residual plant debris and impurities; and concentrating the filtrate using a rotary evaporator under reduced pressure at a temperature between 40°C and 50°C to remove ethanol and obtain a thick, semi-solid herbal extract; wherein the obtained extract is collected and stored separately in sterile beakers for subsequent phytosomal formulation.
4. The process as claimed in claim 3, wherein the plant powder-to-solvent ratio is maintained between 1:5 and 1:10 (w / v) to optimize extraction yield and efficiency.
5. The process as claimed in claim 2, wherein the phytosomal mixture preparation comprising: introducing 100 mg of ethanolic herbal extracts of Bauhinia variegata and Centella asiatica into a sterilized round-bottom flask; adding 100-200 mg of soy lecithin to the flask in a weight-to-weight ratio ranging from 1:1 to 1:2 with respect to the herbal extract; preparing a solvent mixture comprising 10 mL of ethanol and 20 mL of tetrahydrofuran (THF) and adding to the flask containing the extract and lecithin; and subjecting the resultant mixture to a magnetic stirring at room temperature for 30 to 45 minutes to achieve complete dissolution and uniform mixing, thereby forming a homogeneous phytosomal mixture suitable for subsequent thin film formation.
6. The process as claimed in claim 5, wherein the temperature during mixing is maintained between 25°C and 30°C to preserve the thermolabile phytoconstituents of the herbal extract.
7. The process as claimed in claim 2, wherein the thin phytosomal film is obtained by: subjecting the phytosomal mixture to a rotary evaporation; maintaining the rotary evaporation under a controlled temperature range of 40°C to 45°C and under reduced pressure conditions; rotating the round-bottom flask to ensure uniform solvent removal and even film deposition; and evaporating the solvent mixture until a thin, dry phytosomal film is formed on the inner wall of the flask, wherein the obtained thin film serves as a precursor for hydration and nanoscale vesicle formation.
8. The process as claimed in claim 7, wherein the rotary evaporation is carried out at a vacuum pressure ranging from 200 to 300 mbar to prevent thermal degradation of phytoconstituents during solvent removal, wherein the evaporation continues for a duration between 30 and 60 minutes until complete dryness of the solvent mixture is achieved.
9. The process as claimed in claim 2, wherein hydration is carried out using distilled or deionized water at a temperature between 25°C and 35°C to ensure optimal swelling and vesicle formation, wherein probe sonication is performed at an amplitude of 40%-60% for a duration of 5-10 minutes to achieve a vesicle size below 250 nanometers.
10. The process as claimed in claim 2, wherein the lyophilization is performed at a condenser temperature ranging from -45°C to -55°C and a chamber pressure between 0.01 and 0.05 mbar to promote sublimation of ice without structural collapse of phytosomal vesicles, wherein the frozen dispersion is pre-frozen using a controlled rate freezer to minimize ice crystal formation and preserve vesicle integrity, wherein a cryoprotectant selected from mannitol, trehalose, or sucrose is optionally added to the dispersion prior to freezing in an amount ranging from 1% to 5% w / v to prevent aggregation during freeze-drying.
